Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Fda Inspections
  6. /
  7. Glaxo Operations U.K. Ltd.
FDA Inspection
•Glaxo Operations U.K. Ltd.•September 17, 2019

Glaxo Operations U.K. Ltd. – FDA Inspection, Sep 17, 2019

Record Details

This FDA Inspection record concerns Glaxo Operations U.K. Ltd., with an inspection on September 17, 2019, issued by the Office of Inspections and Investigations, covering human drugs.

Company
Glaxo Operations U.K. Ltd.
Inspection Date
September 17, 2019
Product Type
Human Drugs
Office
Office of Inspections and Investigations
People
  • Kumar G. Janoria (Issuing Officer)
  • Maya M. Davis (FDA Associated Person)
View Company Profile

ID · 8391bdd5-8330-4bf7-97ff-df96b7424ec8

Inspection Facts

Voluntary Action Indicated (VAI)

Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.

Inspection number
1107134
FDA center
Human Drugs
Project area
New Drug Evaluation
Outcome
Form 483 issued

FDA Citations

9
  1. 21 CFR 211.100(a)Absence of Written Procedures
  2. 21 CFR 211.165(e)Test methods
  3. 21 CFR 211.186(b)(7)Theoretical yield statement including percentages
  4. 21 CFR 211.188Prepared for each batch, include complete information
  5. 21 CFR 211.192Investigations of discrepancies, failures
  6. 21 CFR 211.22(d)Procedures not in writing, fully followed
  7. 21 CFR 211.25(a)Training--operations, GMPs, written procedures
  8. 21 CFR 211.42(c)Defined areas of adequate size for operations
  9. 21 CFR 211.67(a)Cleaning / Sanitizing / Maintenance

Full citation text and observation details available on the Dashboard.

Other FDA inspections of Glaxo Operations U.K. Ltd.

10
DateClassificationOfficeProject area
March 16, 2023Not classifiedOffice of Inspections and Investigations
February 10, 2023VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
July 4, 2017Not classifiedOffice of Inspections and Investigations
June 2, 2017VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
June 23, 2015VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
View all 10 other inspections on the company page
Other documents for Glaxo Operations U.K. Ltd.
  • FDA Inspection 1211398 - 2023-03-16
  • FDA Inspection 1209851 - 2023-02-10
  • FDA Inspection 1016930 - 2017-07-04
  • FDA Inspection 1014765 - 2017-06-02
  • FDA Inspection 933676 - 2015-06-23

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Glaxo Operations U.K. Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.